Emerging data with immunotherapy in esophageal squamous cell carcinoma and potential impact for clinical practice

Access to this content is not permitted for healthcare professionals based in the US and UK.

Back to Education
Gastrointestinal Oncology, Immunotherapy Watch Time: 35 mins

touchTALKS Emerging data with immunotherapy in esophageal squamous cell carcinoma and potential impact for clinical practice

Join Dr Elizabeth Smyth as she highlights the latest clinical data on the use of immunotherapy in the management of esophageal squamous cell carcinoma (ESCC).

Video Chapters
Insights from 2021

Dr Elizabeth Smyth shares her expert insights in a round-up of the latest data presented at key 2021 oncology congresses on the management of patients with ESCC using immunotherapy.

view bio and disclosures
1/4 Next Chapter
Insights from ASCO and ESMO GI 2022

Dr Elizabeth Smyth shares her expert insights in a round-up of the latest data presented at ASCO and ESMO GI 2022 on the management of patients with ESCC using immunotherapy.

view bio and disclosures
2/4 Next Chapter
Updated ESMO Clinical Practice Guideline for esophageal squamous cell carcinoma and insights from 2022 on potential future treatment options

Dr Elizabeth Smyth discusses the updated ESMO Clinical Practice Guideline for the treatment of patients with ESCC and shares her expert insights on potential future treatment options.

view bio and disclosures
3/4 Next Chapter
TO FOLLOW - Overview of key 2023 congresses

Overview of key trial data presented across key 2023 congresses

Comparison of the efficacy and safety data

Implications for provision of standard of care in the future

view bio and disclosures
4/4 Leave Feedback
Leave Feedback
Learning Objectives & Overview

In this activity, Dr Elizabeth Smyth, a consultant in gastrointestinal oncology, shares her expert insight and interpretation of the latest advances in the management of patients with esophageal squamous cell carcinoma (ESCC) using immunotherapy, as well as the potential implications for clinical practice.


Learning Objectives

After watching this activity, participants should be better able to:

  • Describe the efficacy data for emerging treatments, including first- and second-line immunotherapy, for ESCC
  • Recall the safety data for emerging treatments for ESCC
  • Discuss how the latest data for emerging treatments for ESCC could impact clinical practice
Faculty & Disclosures
Dr Elizabeth Smyth

Addenbrooke’s Hospital, Cambridge, UK

Elizabeth (Lizzy) Smyth is a consultant in gastrointestinal (GI) oncology at Addenbrooke’s Hospital in Cambridge, UK. Dr Smyth commenced her oncology training in Dublin, Ireland. In 2009 she was awarded an Irish Society of Medical Oncology fellowship to train at Memorial Sloan Kettering Cancer Center, New York, NY, USA. Following this, she worked at the Royal Marsden Hospital in London, UK from 2011 to 2018. Her research focus is on clinical trials and translational research in gastroesophageal cancer and she has worked on trial design and management of national and international trials. She is a member of the European Society of Medical Oncology (ESMO) GI Educational Committee and leads the European Organisation for Research and Treatment of Cancer (EORTC) GI Trials Group Gastric Cancer Taskforce. Dr Smyth is committed to furthering national and international collaboration in GI trials research.

Dr Elizabeth Smyth discloses: Consultancy/advisory fees from AMAL Therapeutics, AstraZeneca, BeiGene, Bristol Myers Squibb, Merck, Novartis, Pfizer, Roche, Servier and Zymeworks; and Grant/research funding from Bristol Myers Squibb.


View and download resources from this activity to support your learning and share with colleagues

Register to touchONCOLOGY for FREE
  • Peer-reviewed journals and expert opinions
  • Interactive CME and e-learning modules
  • Video conference highlights
Register For Free Now
Feedback Close

Please provide feedback for this touchTALKS on the following
(scale 1-5, 1 strongly disagree; 5 strongly agree):

* = Mandatory Field

Feedback Close
Copied to clipboard!
accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72